BioCentury | Sep 3, 2012
Clinical News

BV-NSCLC-001: Phase III started

...NSCLC. Bioven has rights to the vaccine from the Center of Molecular Immunology (Havana, Cuba). Bioven Ltd....
BioCentury | Jun 14, 2004
Finance

Ebb & Flow

...operating loss of $7.4 million and had $33.2 million in cash. Prior to the offering, Bioven...
BioCentury | Dec 22, 2003
Finance

Ebb & Flow

...an IPO, other than to say "we're monitoring the market." The company's significant shareholders include Bioven...
BioCentury | Mar 5, 2001
Finance

Ebb & Flow

...its BNP7787 chemoprotectant to prevent nerve damage associated with paclitaxel chemotherapy. Prior to the offering, Bioven...
BioCentury | Jan 8, 1996
Emerging Company Profile

BioNumerik Pharmaceuticals Inc.

...Southwestern Bell Corp.; USAA Inc.; B.P. Investment Partners; Kinetic Concepts Inc. ; Woodside Fund and Bioven...
Items per page:
1 - 5 of 5
BioCentury | Sep 3, 2012
Clinical News

BV-NSCLC-001: Phase III started

...NSCLC. Bioven has rights to the vaccine from the Center of Molecular Immunology (Havana, Cuba). Bioven Ltd....
BioCentury | Jun 14, 2004
Finance

Ebb & Flow

...operating loss of $7.4 million and had $33.2 million in cash. Prior to the offering, Bioven...
BioCentury | Dec 22, 2003
Finance

Ebb & Flow

...an IPO, other than to say "we're monitoring the market." The company's significant shareholders include Bioven...
BioCentury | Mar 5, 2001
Finance

Ebb & Flow

...its BNP7787 chemoprotectant to prevent nerve damage associated with paclitaxel chemotherapy. Prior to the offering, Bioven...
BioCentury | Jan 8, 1996
Emerging Company Profile

BioNumerik Pharmaceuticals Inc.

...Southwestern Bell Corp.; USAA Inc.; B.P. Investment Partners; Kinetic Concepts Inc. ; Woodside Fund and Bioven...
Items per page:
1 - 5 of 5